Redeye leaves a comment following Alzinova’s announcement of updated in-depth analysis of data from part A of Alzinova's phase 1b study with the vaccine candidate ALZ-101. We are encouraged to learn that patients who experienced elevated antibody levels after treatment respond positively to biomarkers associated with Alzheimer's disease.